Symbols / CSBR $5.90 -1.17%
CSBR Chart
About
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform to provide research services that assist in the drug development process of pharmaceutical and biotechnology companies. In addition, the company offers Lumin Bioinformatics, an oncology data-driven software program which contains comprehensive information derived from research services and clinical studies. It markets its products through internet and sales force to pharmaceutical and biotechnology companies. The company was formerly known as Champions Biotechnology, Inc. and changed its name to Champions Oncology, Inc. in April 2011. Champions Oncology, Inc. was incorporated in 1985 and is headquartered in Hackensack, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 81.93M |
| Enterprise Value | 78.89M | Income | 2.49M | Sales | 58.42M |
| Book/sh | 0.30 | Cash/sh | 0.61 | Dividend Yield | — |
| Payout | 0.00% | Employees | 213 | IPO | — |
| P/E | 34.71 | Forward P/E | 59.00 | PEG | — |
| P/S | 1.40 | P/B | 19.67 | P/C | — |
| EV/EBITDA | 19.87 | EV/Sales | 1.35 | Quick Ratio | 0.91 |
| Current Ratio | 0.96 | Debt/Eq | 127.91 | LT Debt/Eq | — |
| EPS (ttm) | 0.17 | EPS next Y | 0.10 | EPS Growth | -61.10% |
| Revenue Growth | 11.50% | Earnings | 2026-03-12 | ROA | 5.56% |
| ROE | 98.94% | ROIC | — | Gross Margin | 50.11% |
| Oper. Margin | 1.23% | Profit Margin | 4.26% | Shs Outstand | 13.89M |
| Shs Float | 5.19M | Short Float | 1.11% | Short Ratio | 12.94 |
| Short Interest | — | 52W High | 10.25 | 52W Low | 5.59 |
| Beta | 0.40 | Avg Volume | 11.59K | Volume | 15.24K |
| Target Price | — | Recom | None | Prev Close | $5.97 |
| Price | $5.90 | Change | -1.17% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$5.90
Latest analyst target
3. DCF / Fair value
$6.30
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$5.90
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-03-12 | main | Craig-Hallum | Buy → Buy | $12 |
| 2024-12-12 | main | Craig-Hallum | Buy → Buy | $8 |
| 2024-09-12 | up | Craig-Hallum | Hold → Buy | $6 |
| 2024-03-13 | down | Craig-Hallum | Buy → Hold | — |
| 2023-09-22 | main | Roth MKM | Buy → Buy | $8 |
| 2021-03-15 | main | Roth Capital | — → Buy | $16 |
| 2019-11-18 | init | Benchmark | — → Speculative Buy | $11 |
| 2019-09-20 | init | Roth Capital | — → Buy | $9 |
| 2019-07-24 | down | Janney Montgomery Scott | Buy → Neutral | — |
| 2018-07-17 | init | Craig-Hallum | — → Buy | $12 |
| 2018-05-15 | init | Dawson James | — → Buy | $10 |
- CSBR SEC Filings - Champions Oncolo 10-K, 10-Q, 8-K Forms - Stock Titan Wed, 04 Mar 2026 13
- Is Champions Oncology, Inc.'s (NASDAQ:CSBR) Latest Stock Performance A Reflection Of Its Financial Health? - Yahoo Finance Sat, 17 Jan 2026 08
- The Market Lifts Champions Oncology, Inc. (NASDAQ:CSBR) Shares 27% But It Can Do More - simplywall.st ue, 16 Sep 2025 07
- Behavioral Patterns of CSBR and Institutional Flows - Stock Traders Daily ue, 03 Mar 2026 03
- Earnings Preview: CSBR to Report Financial Results Post-market on March 12 - 富途牛牛 Sat, 07 Mar 2026 01
- Champions Oncology Reports Record Quarterly Service Revenue of $14.9 Million - ACCESS Newswire Mon, 15 Dec 2025 08
- (CSBR) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily Fri, 20 Feb 2026 02
- Shareholders in Champions Oncology (NASDAQ:CSBR) are in the red if they invested five years ago - Yahoo Finance Sun, 07 Dec 2025 08
- Earnings call transcript: Champions Oncology Q2 2025 sees strong revenue growth - Investing.com Mon, 15 Dec 2025 08
- Champions Oncology: Biological IP Is The Real Asset - Not Preclinical Services - Seeking Alpha Mon, 16 Jun 2025 07
- Champions Oncology (CSBR) Earnings Transcript - AOL.com Wed, 07 Jan 2026 08
- Argenx, Navan And 3 Stocks To Watch Heading Into Monday - Benzinga Mon, 15 Dec 2025 08
- CHAMPIONS ONCOLOGY, INC. SEC 10-Q Report - TradingView Mon, 15 Dec 2025 08
- CSBR - Finviz Fri, 22 Apr 2016 18
- Is Smurfit Westrock Plc stock supported by strong cash flows - Quarterly Risk Review & Real-Time Stock Price Movement Reports - Naître et grandir Sat, 07 Mar 2026 01
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 94405 | 198250 | — | Conversion of Exercise of derivative security at price 2.10 per share. | ACKERMAN JOEL | Director | — | 2025-10-30 00:00:00 | D |
| 1 | 105137 | 276289 | — | Conversion of Exercise of derivative security at price 2.10 - 5.43 per share. | ACKERMAN JOEL | Director | — | 2024-10-31 00:00:00 | D |
Financials
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -61.53K | -2.17K | -169.47K | 0.00 |
| TaxRateForCalcs | 0.21 | 0.01 | 0.21 | 0.06 |
| NormalizedEBITDA | 6.78M | -4.62M | -1.40M | 2.23M |
| TotalUnusualItems | -293.00K | -435.00K | -807.00K | 0.00 |
| TotalUnusualItemsExcludingGoodwill | -293.00K | -435.00K | -807.00K | 0.00 |
| NetIncomeFromContinuingOperationNetMinorityInterest | 4.70M | -7.28M | -5.33M | 548.00K |
| ReconciledDepreciation | 1.64M | 1.87M | 2.25M | 1.63M |
| ReconciledCostOfRevenue | 28.39M | 29.40M | 29.53M | 23.63M |
| EBITDA | 6.49M | -5.05M | -2.20M | 2.23M |
| EBIT | 4.85M | -6.92M | -4.45M | 607.00K |
| NormalizedIncome | 4.93M | -6.84M | -4.70M | 548.00K |
| NetIncomeFromContinuingAndDiscontinuedOperation | 4.70M | -7.28M | -5.33M | 548.00K |
| TotalExpenses | 52.10M | 57.08M | 58.32M | 48.50M |
| TotalOperatingIncomeAsReported | 4.55M | -7.36M | -5.26M | 607.00K |
| DilutedAverageShares | 14.27M | 13.55M | 13.54M | 14.16M |
| BasicAverageShares | 13.66M | 13.55M | 13.54M | 13.20M |
| DilutedEPS | 0.33 | -0.54 | -0.39 | 0.04 |
| BasicEPS | 0.34 | -0.54 | -0.39 | 0.04 |
| DilutedNIAvailtoComStockholders | 4.70M | -7.28M | -5.33M | 548.00K |
| NetIncomeCommonStockholders | 4.70M | -7.28M | -5.33M | 548.00K |
| NetIncome | 4.70M | -7.28M | -5.33M | 548.00K |
| NetIncomeIncludingNoncontrollingInterests | 4.70M | -7.28M | -5.33M | 548.00K |
| NetIncomeContinuousOperations | 4.70M | -7.28M | -5.33M | 548.00K |
| TaxProvision | -75.00K | -32.00K | 68.00K | 35.00K |
| PretaxIncome | 4.63M | -7.31M | -5.27M | 583.00K |
| OtherIncomeExpense | -220.00K | -387.00K | -818.00K | -24.00K |
| OtherNonOperatingIncomeExpenses | 73.00K | 48.00K | -11.00K | -24.00K |
| SpecialIncomeCharges | -293.00K | -435.00K | -807.00K | 0.00 |
| GainOnSaleOfPPE | -293.00K | -435.00K | 0.00 | |
| WriteOff | 0.00 | 807.00K | 0.00 | |
| ImpairmentOfCapitalAssets | 0.00 | |||
| OperatingIncome | 4.85M | -6.92M | -4.45M | 607.00K |
| OperatingExpense | 23.71M | 27.68M | 28.79M | 24.87M |
| ResearchAndDevelopment | 6.83M | 9.54M | 11.54M | 9.37M |
| SellingGeneralAndAdministration | 16.88M | 18.13M | 17.24M | 15.50M |
| SellingAndMarketingExpense | 7.54M | 7.06M | 7.00M | 6.38M |
| GeneralAndAdministrativeExpense | 9.34M | 11.07M | 10.24M | 9.12M |
| OtherGandA | 9.34M | 11.07M | 10.24M | 9.12M |
| GrossProfit | 28.55M | 20.75M | 24.34M | 25.48M |
| CostOfRevenue | 28.39M | 29.40M | 29.53M | 23.63M |
| TotalRevenue | 56.94M | 50.16M | 53.87M | 49.11M |
| OperatingRevenue | 56.94M | 50.16M | 53.87M | 46.88M |
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | |
|---|---|---|---|---|
| TreasurySharesNumber | 120.33K | 120.33K | 14.42K | |
| OrdinarySharesNumber | 13.78M | 13.59M | 13.54M | 13.52M |
| ShareIssued | 13.90M | 13.71M | 13.56M | 13.52M |
| TotalDebt | 6.11M | 7.43M | 8.60M | 9.47M |
| TangibleBookValue | 3.44M | -2.24M | 4.30M | 8.76M |
| InvestedCapital | 3.77M | -1.90M | 4.64M | 9.10M |
| WorkingCapital | -1.48M | -7.90M | -2.28M | 2.19M |
| NetTangibleAssets | 3.44M | -2.24M | 4.30M | 8.76M |
| CapitalLeaseObligations | 6.11M | 7.43M | 8.60M | 9.47M |
| CommonStockEquity | 3.77M | -1.90M | 4.64M | 9.10M |
| TotalCapitalization | 3.77M | -1.90M | 4.64M | 9.10M |
| TotalEquityGrossMinorityInterest | 3.77M | -1.90M | 4.64M | 9.10M |
| StockholdersEquity | 3.77M | -1.90M | 4.64M | 9.10M |
| TreasuryStock | 708.00K | 708.00K | 74.00K | 0.00 |
| RetainedEarnings | -79.89M | -84.59M | -77.32M | -71.98M |
| AdditionalPaidInCapital | 84.36M | 83.38M | 82.01M | 81.06M |
| CapitalStock | 14.00K | 14.00K | 14.00K | 14.00K |
| CommonStock | 14.00K | 14.00K | 14.00K | 14.00K |
| TotalLiabilitiesNetMinorityInterest | 28.57M | 28.04M | 29.68M | 26.28M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 4.72M | 6.49M | 7.94M | 8.80M |
| OtherNonCurrentLiabilities | 85.00K | 401.00K | 551.00K | 391.00K |
| LongTermDebtAndCapitalLeaseObligation | 4.63M | 6.09M | 7.39M | 8.41M |
| LongTermCapitalLeaseObligation | 4.63M | 6.09M | 7.39M | 8.41M |
| CurrentLiabilities | 23.85M | 21.54M | 21.73M | 17.48M |
| OtherCurrentLiabilities | 135.00K | 150.00K | 145.00K | 72.00K |
| CurrentDeferredLiabilities | 15.44M | 12.09M | 12.78M | 11.07M |
| CurrentDeferredRevenue | 15.44M | 12.09M | 12.78M | 11.07M |
| CurrentDebtAndCapitalLeaseObligation | 1.47M | 1.34M | 1.21M | 1.05M |
| CurrentCapitalLeaseObligation | 1.47M | 1.34M | 1.21M | 1.05M |
| PayablesAndAccruedExpenses | 6.80M | 7.96M | 7.60M | 5.28M |
| CurrentAccruedExpenses | 2.56M | 2.16M | 2.27M | 2.41M |
| Payables | 4.25M | 5.80M | 5.33M | 2.87M |
| AccountsPayable | 4.25M | 5.80M | 5.33M | 2.87M |
| TotalAssets | 32.34M | 26.13M | 34.31M | 35.38M |
| TotalNonCurrentAssets | 9.97M | 12.49M | 14.85M | 15.71M |
| OtherNonCurrentAssets | 185.00K | 185.00K | 15.00K | 15.00K |
| NonCurrentPrepaidAssets | 15.00K | |||
| GoodwillAndOtherIntangibleAssets | 335.00K | 335.00K | 335.00K | 335.00K |
| Goodwill | 335.00K | 335.00K | 335.00K | 335.00K |
| NetPPE | 9.46M | 11.97M | 14.50M | 15.36M |
| AccumulatedDepreciation | -11.69M | -10.39M | -8.63M | -5.58M |
| GrossPPE | 21.14M | 22.36M | 23.13M | 20.94M |
| Leases | 317.00K | 317.00K | 111.00K | 111.00K |
| ConstructionInProgress | 2.01M | 1.89M | 2.97M | 2.07M |
| OtherProperties | 16.40M | 17.76M | 17.71M | 16.85M |
| MachineryFurnitureEquipment | 2.41M | 2.40M | 2.35M | 1.91M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 22.37M | 13.64M | 19.46M | 19.66M |
| OtherCurrentAssets | 1.35M | 1.50M | 1.33M | 1.14M |
| PrepaidAssets | 1.14M | 957.00K | ||
| Receivables | 11.23M | 9.53M | 8.01M | 9.51M |
| ReceivablesAdjustmentsAllowances | -1.03M | -1.30M | -825.00K | -630.00K |
| OtherReceivables | 5.40M | 5.94M | 4.99M | 4.11M |
| AccountsReceivable | 6.87M | 4.89M | 3.84M | 6.04M |
| CashCashEquivalentsAndShortTermInvestments | 9.79M | 2.62M | 10.12M | 9.01M |
| CashAndCashEquivalents | 9.79M | 2.62M | 10.12M | 9.01M |
| CashFinancial | 9.79M | 2.62M | 10.12M | 9.01M |
| Line Item | 2025-04-30 | 2024-04-30 | 2023-04-30 | 2022-04-30 |
|---|---|---|---|---|
| FreeCashFlow | 7.00M | -6.97M | 1.10M | 4.11M |
| RepurchaseOfCapitalStock | 0.00 | -634.00K | -74.00K | 0.00 |
| RepaymentOfDebt | -150.00K | -146.00K | 0.00 | 0.00 |
| CapitalExpenditure | -389.00K | -836.00K | -2.87M | -2.38M |
| EndCashPosition | 9.79M | 2.62M | 10.12M | 9.01M |
| BeginningCashPosition | 2.62M | 10.12M | 9.01M | 4.69M |
| ChangesInCash | 7.17M | -7.50M | 1.11M | 4.32M |
| FinancingCashFlow | 170.00K | -527.00K | 11.00K | 207.00K |
| CashFlowFromContinuingFinancingActivities | 170.00K | -527.00K | 11.00K | 207.00K |
| ProceedsFromStockOptionExercised | 320.00K | 253.00K | 85.00K | 207.00K |
| NetCommonStockIssuance | 0.00 | -634.00K | -74.00K | 0.00 |
| CommonStockPayments | 0.00 | -634.00K | -74.00K | 0.00 |
| NetIssuancePaymentsOfDebt | -150.00K | -146.00K | 0.00 | 0.00 |
| NetLongTermDebtIssuance | -150.00K | -146.00K | 0.00 | 0.00 |
| LongTermDebtPayments | -150.00K | -146.00K | 0.00 | 0.00 |
| InvestingCashFlow | -389.00K | -836.00K | -2.87M | -2.38M |
| CashFlowFromContinuingInvestingActivities | -389.00K | -836.00K | -2.87M | -2.38M |
| NetOtherInvestingChanges | 112.00K | |||
| NetPPEPurchaseAndSale | -389.00K | -836.00K | -2.87M | -2.38M |
| PurchaseOfPPE | -389.00K | -836.00K | -2.87M | -2.38M |
| OperatingCashFlow | 7.39M | -6.14M | 3.97M | 6.50M |
| CashFlowFromContinuingOperatingActivities | 7.39M | -6.14M | 3.97M | 6.50M |
| ChangeInWorkingCapital | -621.00K | -3.82M | 4.24M | 2.34M |
| ChangeInOtherWorkingCapital | 3.35M | -683.00K | 1.71M | 4.82M |
| ChangeInOtherCurrentLiabilities | -1.32M | -1.17M | -907.00K | -631.00K |
| ChangeInOtherCurrentAssets | 0.00 | -169.00K | 0.00 | |
| ChangeInPayablesAndAccruedExpense | -1.35M | 356.00K | 2.32M | 1.16M |
| ChangeInAccruedExpense | 395.00K | -109.00K | -145.00K | 183.00K |
| ChangeInPayable | -1.75M | 465.00K | 2.46M | 974.00K |
| ChangeInAccountPayable | -1.75M | 465.00K | 2.46M | 974.00K |
| ChangeInPrepaidAssets | 144.00K | -167.00K | -184.00K | -187.00K |
| ChangeInReceivables | -1.44M | -1.99M | 1.31M | -2.82M |
| ChangesInAccountReceivables | -1.44M | -1.99M | 1.31M | -2.82M |
| OtherNonCashItems | 1.17M | 1.07M | 952.00K | 786.00K |
| StockBasedCompensation | 654.00K | 1.12M | 864.00K | 912.00K |
| ProvisionandWriteOffofAssets | -272.00K | 476.00K | 195.00K | 292.00K |
| AssetImpairmentCharge | 0.00 | 807.00K | 0.00 | 0.00 |
| DeferredTax | -181.00K | 0.00 | ||
| DeferredIncomeTax | -181.00K | 0.00 | ||
| DepreciationAmortizationDepletion | 1.64M | 1.87M | 2.25M | 1.63M |
| DepreciationAndAmortization | 1.64M | 1.87M | 2.25M | 1.63M |
| OperatingGainsLosses | 293.00K | 435.00K | -4.00K | -75.00K |
| GainLossOnSaleOfPPE | 293.00K | 435.00K | 0.00 | -4.00K |
| NetIncomeFromContinuingOperations | 4.70M | -7.28M | -5.33M | 548.00K |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CSBR
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|